Out-of-network with most major insurers, talk with our admissions team to get started.
CLINICAL FRAMEWORK
Cardiometabolic care in schizophrenia
A strategic plan for preventing and treating the cardiometabolic burden that accompanies psychosis and its treatment, monitoring, pharmacology, exercise, and a phased protocol.
The dual-hit model
Patients with schizophrenia face a synergistic cardiometabolic threat: intrinsic disease vulnerability paired with medication-induced metabolic dysfunction.
Intrinsic risk
Abnormal glucose tolerance and visceral adiposity are often present at the first episode of psychosis, before treatment begins.
Iatrogenic risk
Antipsychotics disrupt H1 and 5HT2C pathways, triggering hyperphagia and weight gain within weeks of initiation.
Relative metabolic risk by medication
Data represents normalized metabolic disruption scores based on weight gain and lipid drift.
Keep reading
All programs & care pages →- Programs & careAntipsychotics & clozapine explorerAn interactive explorer of antipsychotic options and trade-offs.For everyone
- Programs & careWhat is coordinated specialty care?The CSC model, what CSCplus adds, and the unmet needs it addresses.For everyone
- Programs & careAdult psychosis programCalifornia OnTrack coordinated specialty care for adults.For families
- Programs & careWhat we treatEvery condition we treat, with a dedicated page for each.For families